Loading organizations...
Key people at PetBioCell.
PetBioCell provides advanced dendritic cell therapy for animals, an immunotherapy activating the immune system against tumor cells. It offers individualized treatments for dogs, cats, and horses, fostering natural healing. Its specialized laboratory meticulously prepares these cell-based immunotherapies for veterinary use.
PetBioCell was founded by veterinarians Dr. Dr. Dierk Rebeski, CEO, and Dr. Thomas Grammel. Their insight came from over two decades researching dendritic cell therapy, recognizing its potential for oncological treatment in companion animals. This scientific background guides the company's immunobiology focus for veterinary medicine.
PetBioCell serves veterinarians and pet owners seeking innovative treatments for animal diseases. Its vision is to improve pets' long-term quality of life through sustainable veterinary medicine. By integrating advanced cell-based immunotherapy into daily practice, PetBioCell expands therapeutic possibilities and promotes lasting well-being.
PetBioCell GmbH is a German veterinary biotech company based in Osterode am Harz, Lower Saxony, specializing in dendritic cell therapy for treating pet tumors.[2][3][4][5] It develops innovative, gentle immunotherapy solutions that harness animals' own immune cells to combat cancer, serving pet owners and veterinarians seeking alternatives to chemotherapy; the therapy strengthens the immune system without toxic side effects, aiming to extend life expectancy and improve quality of life.[5] Operating in pharmaceutical manufacturing with ties to AI and data analytics, the company processes blood samples from vets in a GMP-certified lab, culturing and returning personalized dendritic cell injections via refrigerated delivery.[4][5] While specific growth metrics are limited, it positions itself as a leader in veterinary dendritic cell therapy in Germany.[2]
PetBioCell GmbH is registered in Osterode, Germany, under the Göttingen Local Court (HRB 201822), operating in the wholesale of medical, orthopedic, dental, and lab equipment, with additional focus on pharmaceutical manufacturing.[1][3][4] Limited public details exist on founders or exact founding year beyond its active German entity status and a small team of about 7 employees; its emergence ties to adapting human medicine's dendritic cell approaches to veterinary oncology, likely spurred by demand for non-toxic pet cancer treatments.[2][5] A related UK entity, Petbiocell UK Ltd (company number 10228160), was registered but has since dissolved, suggesting early international expansion attempts that consolidated in Germany.[6] Pivotal traction stems from establishing a GMP-certified clean room lab for scalable, vet-integrated therapy production.[5]
PetBioCell rides the wave of personalized immunotherapy expanding from human oncology to veterinary medicine, fueled by pet humanization trends where owners spend more on advanced treatments (global pet cancer market growing amid rising pet ownership).[2][5] Timing aligns with GMP advancements enabling scalable cell therapies outside human clinics, while market forces like chemotherapy drawbacks and demand for non-toxic options favor its model—especially in Europe with strict animal health regs.[1][5] It influences the ecosystem by pioneering vet-accessible biotech, potentially lowering barriers for immunotherapy adoption and inspiring similar startups in animal health tech.
PetBioCell's niche leadership in vet dendritic cell therapy positions it for expansion amid rising pet cancer cases and immunotherapy hype; next steps likely include scaling lab capacity, international partnerships beyond dissolved UK efforts, and AI-driven personalization for broader tumor types.[2][4][5][6] Trends like vet telehealth integration and sustainable biotech will shape growth, evolving its influence from German specialist to global player in animal precision medicine—bridging human-vet tech gaps for longer, healthier pet lives.
Key people at PetBioCell.
